A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

PHASE2TerminatedINTERVENTIONAL
Enrollment

409

Participants

Timeline

Start Date

January 28, 2013

Primary Completion Date

December 30, 2015

Study Completion Date

December 30, 2015

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Mavrilimumab 100 mg

Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years

Trial Locations (52)

Unknown

Research Site, Ciudad Autonoma Buenos Aires

Research Site, Ciudad Autonoma de Buenos Aire

Research Site, Rosario

Research Site, San Miguel de Tucumán

Research Site, Plovdiv

Research Site, Sofia

Research Site, Santiago

Research Site, Viña del Mar

Research Site, Barranquilla

Research Site, Bruntál

Research Site, Jihlava

Research Site, Ostrava - Trebovice

Research Site, Prague

Research Site, Uherské Hradiště

Research Site, Zlín

Research Site, Tallinn

Research Site, Cologne

Research Site, Magdeburg

Research Site, Athens

Research Site, Larissa

Research Site, Baja

Research Site, Balatonfüred

Research Site, Budapest

Research Site, Debrecen

Research Site, Ashkelon

Research Site, Kfar Saba

Research Site, Petah Tikva

Research Site, Mérida

Research Site, Gdynia

Research Site, Grodzisk Mazowiecki

Research Site, Katowice

Research Site, Krakow

Research Site, Wroclaw

Research Site, Barnaul

Research Site, Kazan'

Research Site, Moscow

Research Site, Saint Petersburg

Research Site, Yaroslavl

Research Site, Belgrade

Research Site, Niška Banja

Research Site, Bratislava

Research Site, Durban

Research Site, Barcelona

Research Site, Málaga

Research Site, Santiago de Compostela

Research Site, Donetsk

Research Site, Kharkiv

Research Site, Kiev

Research Site, Lutsk

Research Site, Vinnytsia

Research Site, Edinburgh

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY